Which has stronger valuation and earnings, TWST or VCYT?

Veracyte has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Twist Bioscience $376.57M 30.96 -$77.67M -$2.22 N/A Veracyte $517.15M 7.08 $66.35M $1.41 32.30

Does the media prefer TWST or VCYT?

In the previous week, Twist Bioscience had 2 more articles in the media than Veracyte. MarketBeat recorded 9 mentions for Twist Bioscience and 7 mentions for Veracyte. Twist Bioscience's average media sentiment score of 0.48 beat Veracyte's score of 0.08 indicating that Twist Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Veracyte 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, EXEL or VCYT?

Exelixis has higher revenue and earnings than Veracyte. Exelixis is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 6.25 $782.57M $3.18 18.40 Veracyte $517.15M 7.08 $66.35M $1.41 32.30

Is EXEL or VCYT more profitable?

Exelixis has a net margin of 35.33% compared to Veracyte's net margin of 20.37%. Exelixis' return on equity of 42.17% beat Veracyte's return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.33% 42.17% 31.76% Veracyte 20.37% 9.26% 8.61%

Does the media favor EXEL or VCYT?

In the previous week, Veracyte had 3 more articles in the media than Exelixis. MarketBeat recorded 7 mentions for Veracyte and 4 mentions for Exelixis. Exelixis' average media sentiment score of 0.74 beat Veracyte's score of 0.08 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veracyte 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ASND or VCYT?

In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Veracyte. MarketBeat recorded 9 mentions for Ascendis Pharma A/S and 7 mentions for Veracyte. Veracyte's average media sentiment score of 0.08 beat Ascendis Pharma A/S's score of -0.02 indicating that Veracyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Veracyte 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer VCYT or HALO?

In the previous week, Veracyte and Veracyte both had 7 articles in the media. Halozyme Therapeutics' average media sentiment score of 0.19 beat Veracyte's score of 0.08 indicating that Halozyme Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Halozyme Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, VCYT or BBIO?

Veracyte has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veracyte $517.15M 7.08 $66.35M $1.41 32.30 BridgeBio Pharma $502.08M 26.20 -$724.93M -$3.57 N/A

Does the media refer more to VCYT or BBIO?

In the previous week, Veracyte had 3 more articles in the media than BridgeBio Pharma. MarketBeat recorded 7 mentions for Veracyte and 4 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.51 beat Veracyte's score of 0.08 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Pharma 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Veracyte (VCYT) Competitors

$45.81 +1.62 (+3.67%)

Closing price 04:00 PM Eastern

Extended Trading

$45.86 +0.04 (+0.10%)

As of 07:09 PM Eastern

Compare

VCYT vs. TWST, EXEL, ASND, HALO, and BBIO

Should you buy Veracyte stock or one of its competitors? Veracyte's main competitors and comparable companies include Twist Bioscience (TWST), Exelixis (EXEL), Ascendis Pharma A/S (ASND), Halozyme Therapeutics (HALO), and BridgeBio Pharma (BBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Veracyte compare to Twist Bioscience?

Twist Bioscience (NASDAQ:TWST) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Veracyte has a net margin of 20.37% compared to Twist Bioscience's net margin of -31.66%. Veracyte's return on equity of 9.26% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Twist Bioscience	-31.66%	-28.64%	-19.94%
Veracyte	20.37%	9.26%	8.61%

Veracyte has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Twist Bioscience	$376.57M	30.96	-$77.67M	-$2.22	N/A
Veracyte	$517.15M	7.08	$66.35M	$1.41	32.30

In the previous week, Twist Bioscience had 2 more articles in the media than Veracyte. MarketBeat recorded 9 mentions for Twist Bioscience and 7 mentions for Veracyte. Twist Bioscience's average media sentiment score of 0.48 beat Veracyte's score of 0.08 indicating that Twist Bioscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Twist Bioscience	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Veracyte	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Twist Bioscience presently has a consensus price target of $115.27, indicating a potential downside of 38.00%. Veracyte has a consensus price target of $55.78, indicating a potential upside of 22.46%. Given Veracyte's stronger consensus rating and higher probable upside, analysts plainly believe Veracyte is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Twist Bioscience	2 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
Veracyte	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Twist Bioscience has a beta of 2.19, indicating that its share price is 119% more volatile than the broader market. Comparatively, Veracyte has a beta of 1.95, indicating that its share price is 95% more volatile than the broader market.

Summary

Veracyte beats Twist Bioscience on 10 of the 15 factors compared between the two stocks.

How does Veracyte compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

Exelixis has a net margin of 35.33% compared to Veracyte's net margin of 20.37%. Exelixis' return on equity of 42.17% beat Veracyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Veracyte	20.37%	9.26%	8.61%

85.3% of Exelixis shares are held by institutional investors. 2.6% of Exelixis shares are held by company insiders. Comparatively, 1.6% of Veracyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Exelixis has higher revenue and earnings than Veracyte. Exelixis is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.25	$782.57M	$3.18	18.40
Veracyte	$517.15M	7.08	$66.35M	$1.41	32.30

In the previous week, Veracyte had 3 more articles in the media than Exelixis. MarketBeat recorded 7 mentions for Veracyte and 4 mentions for Exelixis. Exelixis' average media sentiment score of 0.74 beat Veracyte's score of 0.08 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veracyte	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Exelixis presently has a consensus target price of $50.29, indicating a potential downside of 14.07%. Veracyte has a consensus target price of $55.78, indicating a potential upside of 22.46%. Given Veracyte's stronger consensus rating and higher possible upside, analysts clearly believe Veracyte is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Veracyte	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Exelixis has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market. Comparatively, Veracyte has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market.

Summary

Exelixis beats Veracyte on 9 of the 16 factors compared between the two stocks.

How does Veracyte compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

Ascendis Pharma A/S presently has a consensus target price of $310.75, indicating a potential upside of 37.31%. Veracyte has a consensus target price of $55.78, indicating a potential upside of 22.46%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, equities analysts clearly believe Ascendis Pharma A/S is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00
Veracyte	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Ascendis Pharma A/S has a net margin of 70.99% compared to Veracyte's net margin of 20.37%. Ascendis Pharma A/S's return on equity of 32.54% beat Veracyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Veracyte	20.37%	9.26%	8.61%

In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Veracyte. MarketBeat recorded 9 mentions for Ascendis Pharma A/S and 7 mentions for Veracyte. Veracyte's average media sentiment score of 0.08 beat Ascendis Pharma A/S's score of -0.02 indicating that Veracyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Veracyte	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Veracyte has lower revenue, but higher earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	17.33	-$258M	$12.89	17.56
Veracyte	$517.15M	7.08	$66.35M	$1.41	32.30

Ascendis Pharma A/S has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Veracyte has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market.

Summary

Ascendis Pharma A/S beats Veracyte on 9 of the 15 factors compared between the two stocks.

How does Veracyte compare to Halozyme Therapeutics?

Veracyte (NASDAQ:VCYT) and Halozyme Therapeutics (NASDAQ:HALO) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Veracyte currently has a consensus target price of $55.78, indicating a potential upside of 22.46%. Halozyme Therapeutics has a consensus target price of $91.20, indicating a potential downside of 16.55%. Given Veracyte's stronger consensus rating and higher possible upside, equities analysts clearly believe Veracyte is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Halozyme Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

97.8% of Halozyme Therapeutics shares are held by institutional investors. 1.6% of Veracyte shares are held by company insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Halozyme Therapeutics has higher revenue and earnings than Veracyte. Veracyte is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	7.08	$66.35M	$1.41	32.30
Halozyme Therapeutics	$1.40B	8.88	$316.89M	$3.35	32.62

Halozyme Therapeutics has a net margin of 24.86% compared to Veracyte's net margin of 20.37%. Halozyme Therapeutics' return on equity of 260.98% beat Veracyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	20.37%	9.26%	8.61%
Halozyme Therapeutics	24.86%	260.98%	23.91%

In the previous week, Veracyte and Veracyte both had 7 articles in the media. Halozyme Therapeutics' average media sentiment score of 0.19 beat Veracyte's score of 0.08 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Halozyme Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Veracyte has a beta of 1.95, indicating that its share price is 95% more volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

Summary

Halozyme Therapeutics beats Veracyte on 12 of the 16 factors compared between the two stocks.

How does Veracyte compare to BridgeBio Pharma?

Veracyte (NASDAQ:VCYT) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.

Veracyte has a beta of 1.95, suggesting that its stock price is 95% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

Veracyte presently has a consensus target price of $55.78, indicating a potential upside of 22.46%. BridgeBio Pharma has a consensus target price of $102.61, indicating a potential upside of 52.50%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Veracyte has a net margin of 20.37% compared to BridgeBio Pharma's net margin of -97.03%. Veracyte's return on equity of 9.26% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	20.37%	9.26%	8.61%
BridgeBio Pharma	-97.03%	N/A	-61.19%

In the previous week, Veracyte had 3 more articles in the media than BridgeBio Pharma. MarketBeat recorded 7 mentions for Veracyte and 4 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.51 beat Veracyte's score of 0.08 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Pharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.9% of BridgeBio Pharma shares are owned by institutional investors. 1.6% of Veracyte shares are owned by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Veracyte has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	7.08	$66.35M	$1.41	32.30
BridgeBio Pharma	$502.08M	26.20	-$724.93M	-$3.57	N/A

Summary

Veracyte beats BridgeBio Pharma on 10 of the 17 factors compared between the two stocks.

Get Veracyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VCYT vs. The Competition

Export

Metric	Veracyte	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.68B	$3.84B	$7.10B	$13.24B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	32.49	12.99	274.61	26.05
Price / Sales	7.12	1,288.54	601.02	89.39
Price / Cash	30.91	121.76	77.38	51.25
Price / Book	2.76	16.63	10.92	6.31
Net Income	$66.35M	-$22.67M	$3.50B	$361.43M
7 Day Performance	0.84%	-3.06%	-2.11%	-1.67%
1 Month Performance	2.07%	-10.76%	-6.34%	-3.94%
1 Year Performance	28.57%	21.10%	8.81%	2.77%

Veracyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VCYT Veracyte	4.1617 of 5 stars	$45.81 +3.7%	$55.78 +21.8%	+22.0%	$3.68B	$517.15M	32.49	755
TWST Twist Bioscience	1.2795 of 5 stars	$179.60 -1.8%	$103.00 -42.7%	+542.7%	$11.46B	$376.57M	N/A	979	Analyst Forecast
EXEL Exelixis	3.1761 of 5 stars	$58.37 +0.4%	$50.29 -13.9%	+40.6%	$14.41B	$2.32B	18.36	1,077
ASND Ascendis Pharma A/S	4.7691 of 5 stars	$230.05 +2.0%	$310.75 +35.1%	+11.4%	$14.07B	$814.57M	17.85	1,189
HALO Halozyme Therapeutics	2.746 of 5 stars	$112.89 -0.9%	$91.20 -19.2%	+42.7%	$12.93B	$1.40B	33.70	423	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VCYT) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veracyte (VCYT) Competitors

VCYT vs. TWST, EXEL, ASND, HALO, and BBIO

How does Veracyte compare to Twist Bioscience?

Summary

How does Veracyte compare to Exelixis?

Summary

How does Veracyte compare to Ascendis Pharma A/S?

Summary

How does Veracyte compare to Halozyme Therapeutics?

Summary

How does Veracyte compare to BridgeBio Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCYT vs. The Competition

Veracyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Veracyte (VCYT) Competitors

VCYT vs. TWST, EXEL, ASND, HALO, and BBIO

How does Veracyte compare to Twist Bioscience?

Is TWST or VCYT more profitable?

Which has stronger valuation and earnings, TWST or VCYT?

Does the media prefer TWST or VCYT?

Do analysts prefer TWST or VCYT?

Which has more risk and volatility, TWST or VCYT?

Summary

How does Veracyte compare to Exelixis?

Is EXEL or VCYT more profitable?

Do institutionals and insiders believe in EXEL or VCYT?

Which has better valuation and earnings, EXEL or VCYT?

Does the media favor EXEL or VCYT?

Do analysts recommend EXEL or VCYT?

Which has more risk and volatility, EXEL or VCYT?

Summary

How does Veracyte compare to Ascendis Pharma A/S?

Do analysts recommend ASND or VCYT?

Is ASND or VCYT more profitable?

Does the media favor ASND or VCYT?

Which has preferable earnings and valuation, ASND or VCYT?

Which has more risk & volatility, ASND or VCYT?

Summary

How does Veracyte compare to Halozyme Therapeutics?

Do analysts recommend VCYT or HALO?

Do insiders and institutionals have more ownership in VCYT or HALO?

Which has better valuation & earnings, VCYT or HALO?

Is VCYT or HALO more profitable?

Does the media prefer VCYT or HALO?

Which has more risk & volatility, VCYT or HALO?

Summary

How does Veracyte compare to BridgeBio Pharma?

Which has more volatility & risk, VCYT or BBIO?

Do analysts prefer VCYT or BBIO?

Is VCYT or BBIO more profitable?

Does the media refer more to VCYT or BBIO?

Do institutionals and insiders believe in VCYT or BBIO?

Which has higher earnings & valuation, VCYT or BBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCYT vs. The Competition

Veracyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools